Latest From Uluru Inc.
Pipeline Watch: Phase III Starts With Fitusiran In Hemophilia, Zoliflodacin In Gonorrhea, Opdivo Combo In RCC
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Dr Jeffrey Stone has joined the board of directors at Uluru, a US speciality pharmaceutical company developing a portfolio of wound management and oral care products. Dr Stone is president of Wound Care Consultants and is a past president Texas affiliate of the American Diabetes Association.
In recent years, drug reformulation has emerged as a popular defence strategy among pharmaceutical companies seeking to prolong the life cycles of their best-selling products. It has also attracted growing interest from specialist companies developing novel formulations of off-patent drugs and which either launch them as replacements for the originator products, or reposition them for new indications.
- Nanotechnology, Chips, etc.
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Dental & Oral Products
- Neurology, Nervous System
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
- Uluru Inc.
- Senior Management
Helmut Kerschbaumer , Interim Pres. & CEO
Terrance Wallberg, VP, CFO
- Contact Info
Phone: (214) 905-5145
4452 Beltway Dr.
Addison, TX 75001
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.